Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERITAC-3: ARV-471 (Vepdegestrant) plus Palbociclib vs Letrozole plus Palbociclib in ER+/HER2- Advanced Breast Cancer
jRCT2031230255Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Aug 2023
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of vepdegestrant in breast cancer (2 arms), sponsored by Pfizer. Started Aug 2023; status: active, not recruiting.
02
Drugs
vepdegestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2031230255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230255.